Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy

Trial Profile

Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Expanded access; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 13 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top